+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Peptic Ulcer Drugs Market Report and Forecast 2024-2032

  • PDF Icon

    Report

  • 160 Pages
  • April 2024
  • Region: Global
  • Expert Market Research
  • ID: 5960388

Peptic Ulcer Drugs Market Overview

The peptic ulcer drugs market size was valued at USD 6.12 billion in 2023, driven by the rising prevalence of peptic ulcers across the 8 major markets. The market is expected to grow at a CAGR of 3.80% during the forecast period of 2024-2032, with the values likely to attain USD 8.56 billion by 2032. By 2032, the market is projected to have experienced considerable growth, driven by innovation in drug development, an increase in the geriatric population, and enhanced healthcare infrastructure globally.

The peptic ulcer drugs market has seen substantial growth, propelled by the increasing prevalence of peptic ulcer disease (PUD) globally. This growth is further supported by advancements in medical treatments, rising healthcare expenditures, and growing awareness of the disease. Initially, the market's value was significantly driven by the demand for proton pump inhibitors (PPIs) and H2 receptor antagonists due to their efficacy in reducing gastric acid production. Over the years, the market expanded with the introduction of novel therapeutic agents, improved diagnostic techniques, and a better understanding of PUD's pathophysiology.

Epidemiology

Peptic ulcers affect a considerable portion of the global population, with a notable incidence in both developing and developed countries. The condition is primarily caused by Helicobacter pylori infection and the use of nonsteroidal anti-inflammatory drugs (NSAIDs). The aging population and lifestyle factors such as stress, smoking, and dietary habits have also contributed to the prevalence of PUD.

Peptic Ulcer Drugs Market Drivers and Constraints

The peptic ulcer drugs market is propelled by the growing need for effective treatments against the backdrop of an increasing prevalence of the disease, advancements in medical practices, and rising healthcare spending. However, it faces significant challenges from the development of drug resistance, concerns over the side effects of current therapies, market saturation, regulatory hurdles, and disparities in healthcare access.

Drivers:

  • Rising Prevalence of Peptic Ulcer Disease (PUD): The global increase in cases of peptic ulcers, driven by factors such as Helicobacter pylori infection and the widespread use of nonsteroidal anti-inflammatory drugs (NSAIDs), serves as a primary driver for the market. The aging population, which is more susceptible to ulcers due to physiological changes and higher medication use, further amplifies this demand.
  • Technological Advancements in Diagnosis and Treatment: Innovations in diagnostic techniques, such as endoscopy and urea breath tests, have improved the detection of peptic ulcers and H. pylori infection, facilitating early and accurate treatment. Similarly, advancements in drug delivery systems and the development of novel therapeutic agents enhance treatment efficacy and patient compliance, contributing to market growth.
  • Increased Healthcare Spending and Infrastructure: Growing healthcare expenditures and improvements in healthcare infrastructure, especially in developing countries, have made advanced ulcer treatments more accessible. This expansion in healthcare facilities supports the broader distribution and adoption of peptic ulcer drugs.
  • Heightened Awareness and Education: Enhanced efforts by healthcare providers and public health campaigns to educate the population about the risks associated with NSAID overuse and the importance of early treatment for peptic ulcer symptoms have led to increased patient outreach for medical intervention.

Constraints

  • Development of Drug Resistance: The emergence of antibiotic-resistant strains of Helicobacter pylori presents a significant challenge to the eradication efforts and effectiveness of current treatment regimens. This resistance necessitates ongoing research and development costs to formulate new or combination therapies, impacting market dynamics.
  • Adverse Effects and Long-term Use Concerns of Proton Pump Inhibitors (PPIs): While PPIs are a cornerstone in peptic ulcer treatment, concerns over their long-term use and associated risks, such as nutrient malabsorption, kidney disease, and fractures, have led to cautious prescribing practices. Patients and healthcare providers are increasingly seeking alternative treatments with fewer side effects, affecting the market share of PPIs.
  • Market Saturation and Generic Penetration: The peptic ulcer drug market faces saturation with numerous generic versions of previously patented drugs, leading to intense price competition and reduced profitability for manufacturers. This saturation also makes it challenging for new entrants to establish a strong market presence without significant innovation.
  • Regulatory Hurdles: Stringent regulatory requirements for the approval of new drugs can delay market entry and increase development costs. These hurdles necessitate extensive clinical trials to demonstrate efficacy and safety, prolonging the time to market and impacting the commercial viability of new treatments.
  • Access to Healthcare Services: In many low- and middle-income countries, limited access to healthcare services and diagnostic facilities hampers the early diagnosis and treatment of peptic ulcers. Economic constraints also limit the availability of the latest treatments, affecting market growth in these regions.

Peptic Ulcer Drugs Market Trends and Developments

  • Shift Towards Combination Therapies: There is a growing preference for combination therapies, such as the use of proton pump inhibitors (PPIs) with antibiotics, to effectively treat Helicobacter pylori (H. pylori) infections, which are a major cause of peptic ulcers.
  • Advancements in Proton Pump Inhibitors (PPIs): PPIs remain a cornerstone in peptic ulcer treatment. Research is ongoing to develop newer PPIs with longer duration of action, improved efficacy, and fewer side effects.
  • Increasing Prevalence of H. pylori Infection: The high prevalence of H. pylori infection in certain regions is driving the demand for effective treatment regimens, contributing to the growth of the peptic ulcer drugs market.
  • Growing Awareness and Diagnostic Improvements: Increased awareness about peptic ulcers and advancements in diagnostic techniques, such as endoscopy and urea breath tests, are leading to earlier detection and treatment, thereby supporting market growth.
  • Rising Incidence of NSAID-Induced Ulcers: The widespread use of nonsteroidal anti-inflammatory drugs (NSAIDs) is leading to an increase in NSAID-induced ulcers, driving the demand for protective drugs such as misoprostol and PPIs.
  • Development of Novel Therapeutics: Research is focused on developing novel therapeutic agents, including potassium-competitive acid blockers (P-CABs) and gastroprotective agents, to provide better treatment options for peptic ulcers.

Peptic Ulcer Drugs Market Segmentation

The peptic ulcer drugs market is segmented by product type, disease indication, distribution channel, and region.

Market Breakup by Product Type

  • Proton Pump Inhibitor
  • H2 Antagonist
  • Antibiotics
  • Antacids
  • Ulcer Protective

Market Breakup by Disease Indication

  • Gastritis
  • Gastric Ulcer
  • Duodenal Ulcer
  • GERD
  • Others

Market Breakup by Distribution Channel

  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy
  • Others

Market Breakup by Region

  • United States
  • EU-4 and the United Kingdom
  • Germany
  • France
  • Italy
  • Spain
  • United Kingdom
  • Japan
  • India

Peptic Ulcer Drugs Market: Competitive Landscape

The competitive landscape of the peptic ulcer drugs market is diverse, featuring major pharmaceutical companies, generic drug manufacturers, and biotech firms. Key players involved in the market are Orion Corporation, Bausch Health Companies Inc., CYTOKINETICS, INC., Aquestive Therapeutics, Inc., Sanofi, Covis Pharma, Sun Pharmaceuticals Industries Ltd, Mitsubishi Tanabe Pharma Corporation, BrainStorm Cell Limited, ViroMed Co., Ltd, Ionis Pharmaceuticals, Genervon Biopharmaceuticals, LLC, Biogen, Orphazyme A/S, and F. Hoffmann-La Roche Ltd.

Key players are engaged in developing innovative treatments, expanding their product portfolios, and entering strategic partnerships to enhance their market presence.


This product will be delivered within 5-7 business days.

Table of Contents

1 Preface
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage - Key Segmentation and Scope
1.4 Research Methodology
2 Executive Summary
3 Peptic Ulcer Drugs Market Overview - 8 Major Markets
3.1 Peptic Ulcer Drugs Market Historical Value (2017-2023)
3.2 Peptic Ulcer Drugs Market Forecast Value (2024-2032)
4 Peptic Ulcer Overview
4.1 Guidelines and Stages
4.2 Pathophysiology
4.3 Screening and Diagnosis
4.4 Disease Indication Pathway
5 Patient Profile
5.1 Patient Profile Overview
5.2 Patient Psychology and Emotional Impact Factors
5.3 Risk Assessment and Disease Indication Success Rate
6 Peptic Ulcer Epidemiology Scenario and Forecast - 8 Major Markets
6.1 8MM Epidemiology Scenario Overview (2017-2032)
6.2 United States Peptic Ulcer Epidemiology Scenario and Forecast (2017-2032)
6.3 EU-4 and United Kingdom Peptic Ulcer Epidemiology Scenario and Forecast (2017-2032)
6.3.1 Germany Peptic Ulcer Epidemiology Scenario and Forecast (2017-2032)
6.3.2 France Peptic Ulcer Epidemiology Scenario and Forecast (2017-2032)
6.3.3 Italy Peptic Ulcer Epidemiology Scenario and Forecast (2017-2032)
6.3.4 Spain Peptic Ulcer Epidemiology Scenario and Forecast (2017-2032)
6.3.5 United Kingdom Peptic Ulcer Epidemiology Scenario and Forecast (2017-2032)
6.4 Japan Peptic Ulcer Epidemiology Scenario and Forecast (2017-2032)
6.5 India Peptic Ulcer Epidemiology Scenario and Forecast (2017-2032)
7 Peptic Ulcer Drugs Market Landscape - 8 Major Markets
7.1 Peptic Ulcer: Developers Landscape
7.1.1 Analysis by Year of Establishment
7.1.2 Analysis by Company Size
7.1.3 Analysis by Region
7.2 Peptic Ulcer: Product Landscape
7.2.1 Analysis by Product Type
7.2.2 Analysis by Disease Indication
7.2.3 Analysis by Distribution Channel
8 Peptic Ulcer Challenges and Unmet Needs
8.1 Disease Indication Pathway Challenges
8.2 Compliance and Drop-Out Analysis
8.3 Awareness and Prevention Gaps
9 Cost of Disease Indication
10 Peptic Ulcer Drugs Market Dynamics
10.1 Market Drivers and Constraints
10.2 SWOT Analysis
10.3 Porter’s Five Forces Model
10.4 Key Demand Indicators
10.5 Key Price Indicators
10.6 Industry Events, Initiatives, and Trends
10.7 Value Chain Analysis
11 Peptic Ulcer Drugs Market Segmentation (2017-2032) - 8 Major Markets
11.1 Peptic Ulcer Drugs Market (2017-2032) by Product Type
11.1.1 Market Overview
11.1.2 Proton Pump Inhibitor
11.1.3 H2 Antagonist
11.1.4 Antibiotics
11.1.5 Antacids
11.1.6 Ulcer Protective
11.2 Peptic Ulcer Drugs Market (2017-2032) by Disease Indication
11.2.1 Market Overview
11.2.2 Gastritis
11.2.3 Gastric Ulcer
11.2.4 Duodenal Ulcer
11.2.5 GERD
11.2.6 Others
11.3 Peptic Ulcer Drugs Market (2017-2032) by Distribution Channel
11.3.1 Market Overview
11.3.2 Hospital Pharmacy
11.3.3 Retail Pharmacy
11.3.4 Online Pharmacy
11.3.5 Others
11.4 Peptic Ulcer Drugs Market (2017-2032) by Region
11.4.1 Market Overview
11.4.2 United States
11.4.3 EU-4 and the United Kingdom
11.4.3.1 Germany
11.4.3.2 France
11.4.3.3 Italy
11.4.3.4 Spain
11.4.3.5 United Kingdom
11.4.4 Japan
11.4.5 India
12 United States Peptic Ulcer Drugs Market (2017-2032)
12.1 United States Peptic Ulcer Drugs Market Historical Value (2017-2023)
12.2 United States Peptic Ulcer Drugs Market Forecast Value (2024-2032)
12.3 United States Peptic Ulcer Drugs Market (2017-2032) by Product Type
12.3.1 Market Overview
12.3.2 Proton Pump Inhibitor
12.3.3 H2 Antagonist
12.3.4 Antibiotics
12.3.5 Antacids
12.3.6 Ulcer Protective
12.4 United States Peptic Ulcer Drugs Market (2017-2032) by Disease Indication
12.4.1 Market Overview
12.4.2 Gastritis
12.4.3 Gastric Ulcer
12.4.4 Duodenal Ulcer
12.4.5 GERD
12.4.6 Others
13 EU-4 and United Kingdom Peptic Ulcer Drugs Market (2017-2032)
13.1 EU-4 and United Kingdom Peptic Ulcer Drugs Market Historical Value (2017-2023)
13.2 EU-4 and United Kingdom Peptic Ulcer Drugs Market Forecast Value (2024-2032)
13.3 EU-4 and United Kingdom Peptic Ulcer Drugs Market Overview
13.4 EU-4 and United Kingdom Peptic Ulcer Drugs Market (2017-2032) by Product Type
13.4.1 Market Overview
13.4.2 Proton Pump Inhibitor
13.4.3 H2 Antagonist
13.4.4 Antibiotics
13.4.5 Antacids
13.4.6 Ulcer Protective
13.5 EU-4 and United Kingdom Peptic Ulcer Drugs Market (2017-2032) by Disease Indication
13.5.1 Market Overview
13.5.2 Gastritis
13.5.3 Gastric Ulcer
13.5.4 Duodenal Ulcer
13.5.5 GERD
13.5.6 Others
14 Japan Peptic Ulcer Drugs Market
14.1 Japan Peptic Ulcer Drugs Market Historical Value (2017-2023)
14.2 Japan Peptic Ulcer Drugs Market Forecast Value (2024-2032)
14.3 Japan Peptic Ulcer Drugs Market (2017-2032) by Product Type
14.3.1 Market Overview
14.3.2 Proton Pump Inhibitor
14.3.3 H2 Antagonist
14.3.4 Antibiotics
14.3.5 Antacids
14.3.6 Ulcer Protective
14.4 Japan Peptic Ulcer Drugs Market (2017-2032) by Disease Indication
14.4.1 Market Overview
14.4.2 Gastritis
14.4.3 Gastric Ulcer
14.4.4 Duodenal Ulcer
14.4.5 GERD
14.4.6 Others
15 India Peptic Ulcer Drugs Market
15.1 India Peptic Ulcer Drugs Market (2017-2032) Historical Value (2017-2023)
15.2 India Peptic Ulcer Drugs Market (2017-2032) Forecast Value (2024-2032)
15.3 India Peptic Ulcer Drugs Market (2017-2032) by Product Type
15.3.1 Market Overview
15.3.2 Proton Pump Inhibitor
15.3.3 H2 Antagonist
15.3.4 Antibiotics
15.3.5 Antacids
15.3.6 Ulcer Protective
15.4 India Peptic Ulcer Drugs Market (2017-2032) by Route of Administration
15.4.1 Market Overview
15.4.2 Gastritis
15.4.3 Gastric Ulcer
15.4.4 Duodenal Ulcer
15.4.5 GERD
15.4.6 Others
16 Regulatory Framework
16.1 Regulatory Overview
16.1.1 US FDA
16.1.2 EU EMA
16.1.3 Japan PMDA
16.1.4 Others
17 Patent Analysis
17.1 Analysis by Product Type of Patent
17.2 Analysis by Publication Year
17.3 Analysis by Issuing Authority
17.4 Analysis by Patent Age
17.5 Analysis by CPC Analysis
17.6 Analysis by Patent Valuation
17.7 Analysis by Key Players
18 Grants Analysis
18.1 Analysis by Year
18.2 Analysis by Amount Awarded
18.3 Analysis by Issuing Authority
18.4 Analysis by Grant Application
18.5 Analysis by Funding Institute
18.6 Analysis by NIH Departments
18.7 Analysis by Recipient Organization
19 Clinical Trials Analysis
19.1 Analysis by Trial Registration Year
19.2 Analysis by Trial Status
19.3 Analysis by Trial Phase
19.4 Analysis by Therapeutic Area
19.5 Analysis by Geography
20 Funding and Investment Analysis
20.1 Analysis by Funding Instances
20.2 Analysis by Product Type of Funding
20.3 Analysis by Funding Amount
20.4 Analysis by Leading Players
20.5 Analysis by Leading Investors
20.6 Analysis by Geography
21 Partnership and Collaborations Analysis
21.1 Analysis by Partnership Instances
21.2 Analysis by Product Type of Partnership
21.3 Analysis by Leading Players
21.4 Analysis by Geography
22 Supplier Landscape
22.1 Orion Corporation
22.1.1 Financial Analysis
22.1.2 Product Portfolio
22.1.3 Demographic Reach and Achievements
22.1.4 Mergers and Acquisitions
22.1.5 Certifications
22.2 Bausch Health Companies Inc.
22.2.1 Financial Analysis
22.2.2 Product Portfolio
22.2.3 Demographic Reach and Achievements
22.2.4 Mergers and Acquisitions
22.2.5 Certifications
22.3 CYTOKINETICS, INC.
22.3.1 Financial Analysis
22.3.2 Product Portfolio
22.3.3 Demographic Reach and Achievements
22.3.4 Mergers and Acquisitions
22.3.5 Certifications
22.4 Aquestive Therapeutics, Inc.
22.4.1 Financial Analysis
22.4.2 Product Portfolio
22.4.3 Demographic Reach and Achievements
22.4.4 Mergers and Acquisitions
22.4.5 Certifications
22.5 Sanofi
22.5.1 Financial Analysis
22.5.2 Product Portfolio
22.5.3 Demographic Reach and Achievements
22.5.4 Mergers and Acquisitions
22.5.5 Certifications
22.6 Covis Pharma
22.6.1 Financial Analysis
22.6.2 Product Portfolio
22.6.3 Demographic Reach and Achievements
22.6.4 Mergers and Acquisitions
22.6.5 Certifications
22.7 Sun Pharmaceuticals Industries Ltd
22.7.1 Financial Analysis
22.7.2 Product Portfolio
22.7.3 Demographic Reach and Achievements
22.7.4 Mergers and Acquisitions
22.7.5 Certifications
22.8 Mitsubishi Tanabe Pharma Corporation
22.8.1 Financial Analysis
22.8.2 Product Portfolio
22.8.3 Demographic Reach and Achievements
22.8.4 Mergers and Acquisitions
22.8.5 Certifications
22.9 BrainStorm Cell Limited
22.9.1 Financial Analysis
22.9.2 Product Portfolio
22.9.3 Demographic Reach and Achievements
22.9.4 Mergers and Acquisitions
22.9.5 Certifications
22.10 ViroMed Co., Ltd
22.10.1 Financial Analysis
22.10.2 Product Portfolio
22.10.3 Demographic Reach and Achievements
22.10.4 Mergers and Acquisitions
22.10.5 Certifications
22.11 Ionis Pharmaceuticals
22.11.1 Financial Analysis
22.11.2 Product Portfolio
22.11.3 Demographic Reach and Achievements
22.11.4 Mergers and Acquisitions
22.11.5 Certifications
22.12 Genervon Biopharmaceuticals, LLC
22.12.1 Financial Analysis
22.12.2 Product Portfolio
22.12.3 Demographic Reach and Achievements
22.12.4 Mergers and Acquisitions
22.12.5 Certifications
22.13 Biogen
22.13.1 Financial Analysis
22.13.2 Product Portfolio
22.13.3 Demographic Reach and Achievements
22.13.4 Mergers and Acquisitions
22.13.5 Certifications
22.14 Orphazyme A/S
22.14.1 Financial Analysis
22.14.2 Product Portfolio
22.14.3 Demographic Reach and Achievements
22.14.4 Mergers and Acquisitions
22.14.5 Certifications
22.15 F. Hoffmann-La Roche Ltd
22.15.1 Financial Analysis
22.15.2 Product Portfolio
22.15.3 Demographic Reach and Achievements
22.15.4 Mergers and Acquisitions
22.15.5 Certifications
List not exhaustive!
23 Peptic Ulcer Disease Indication Drugs - Distribution Model (Additional Insight)
23.1 Overview
23.2 Potential Distributors
23.3 Key Parameters for Distribution Partner Assessment
24 Key Opinion Leaders (KOL) Insights (Additional Insight)
25 Company Competitiveness Analysis (Additional Insight)
25.1 Very Small Companies
25.2 Small Companies
25.3 Mid-Sized Companies
25.4 Large Companies
25.5 Very Large Companies
26 Payment Methods (Additional Insight)
26.1 Government Funded
26.2 Private Insurance
26.3 Out-of-Pocket
*Additional insights provided are customisable as per client requirements.
* The coverage of the Market Landscape section depends on the data availability and may cover a minimum of 80% of the total market. The research team strives to make this section as comprehensive as possible.

Companies Mentioned

  • Orion Corporation
  • Bausch Health Companies Inc.
  • CYTOKINETICS INC.
  • Aquestive Therapeutics Inc.
  • Sanofi Covis Pharma
  • Sun Pharmaceuticals Industries Ltd
  • Mitsubishi Tanabe
  • Pharma Corporation
  • BrainStorm Cell Limited
  • ViroMed Co. Ltd
  • Ionis Pharmaceuticals
  • Genervon Biopharmaceuticals LLC
  • Biogen
  • Orphazyme A/S
  • F. Hoffmann-La Roche Ltd

Methodology

Loading
LOADING...